Gaynon P S, Angiolilllo A L, Carroll W L, et al. Long term results of the children’s cancers group studies for childhood acute lymphoblastic leukemia 1983-2002: a Childrens’ Oncology Group report[J].Leukemia, 2010,24(3):285-297.
National Cancer Institute. SEER Cancer Statistics Review,1975-2010[EB/OL].[2013-06-14].http //seer. Cancer.gov/csr/1975-2010
[6]
Rodriguez Galindo C,Friedrich P,Alcasabas P,et al.To-ward the cure of all children with cancer through collabo-rative efforts:pediatric oncology as a global challenge[J].J Clin Oncol,2015,33(27):3065-3073.
Ries L A G, Reichman M E, Lewis D R, et al. Cancer Survival and Incidence from the Surveillance, Epidemiology, and End Results (SEER) Program[J]. Oncologist, 2003, 8(6):541.
Rodriguez Galindo C,Friedrich P,Alcasabas P,et al.To-ward the cure of all children with cancer through collabo-rative efforts:pediatric oncology as a global challenge[J].J Clin Oncol,2015,33(27):3065-3073.
[13]
Lupo P J,Nousome D,Okcu M F,et al.Maternal variation in EPHXl,a xenobiotic metabolism gene,is associated with childhoodmedulloblastoma:an exploratory case-par-ent triad study[J].Pediatric Hematol Oncol,2012,29(8):679-685.
[14]
Watt T C,Inskip P D,Stratton K,et al.Radiation-relatedrisk of basal cell carcinoma:a report from the Childhood Cancer Survivor Study[J].J Natl Cancer Inst,2012,104 (16):1240-1250.
[15]
Council On Environmental Health. Pesticide exposure in children [J].Pediatrics,2012,130(6):1757-1763.
[16]
Zheng J, Li H, Zhu H, et al. Genistein inhibits estradiol and environmental endocrine disruptor-induced growth effects on neuroblastoma cells in vitro[J]. Oncol Lett,2013,5(5):1583-1586.
[17]
Iacob D, Serban A, Fufezan O, et al. Mixed hepatoblastoma in child, case report[J]. Med Ultrason, 2014, 12(2): 157-162.
[18]
Chung E M, Lattin Jr G E, Cube R, et al. From the archives of the AFIP: pediatric liver masses radiologic pathologic correlation malignant tumors[J]. Radiographics, 2011, 39(2): 483-507.
[19]
Ricard F, Cimarelli S, Deshayes E, et al. Additional benifit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma[J]. Clin Nucl Med,2011,36: 672-677.
[20]
London K, Stege C, Cross S, et al. 18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors[J]. Pediatr Radiol,2012,42: 418-430.
[21]
Boltor R R, Omar W S, Mousa E, et al. A preliminary report on the impact of 18F-FDG PET/CT in the management of pediatric head and neck cancer[J]. Nucl Med Commun,2012,33: 21-28.
[22]
Klenk C, Gawande R, Usu L, et al. Ionising radiation-free wholebody MRI versus 18F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, no-randomised, single-centre study[J]. Lancet Oncol,2014,15: 275-285.
[23]
AI-Bulushi N K, Abouzied M E. Comparison of 18F-FDG PET/CT scan and 99Tcm -MDP bone scintigraphy in detecting bonemetastasis in head and neck tumors[J]. Nucl Med Commun, 2016, 37(6): 583-588.
[24]
Gabriele D, Collura D,Oderda M, et al. Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database[J]. World J Urol, 2016, 34(4): 517-523.
[25]
Hillner B E, Eiegel B A, Hanna L. 18F-Fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry[J]. J Nucl Med, 2015, 56(2): 222-228.
[26]
Fassina A, Klijanienko J. Multidisciplinary and multimodal diagnostic approach in paediatric tumours combining fine needle aspiration, core needle biopsy and ancillary techniques[J]. Cytopathology, 2014, 25(1):3.
Park J R, Bagatell R, Cohn S L, et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the national cancer institute clinical trials planning meeting[J]. J Clin Oncol, 2017, 35 (22): 2580-2587.
[34]
Whittle S B, Smith V, Doherty E, et al. Overview and recent advances in the treatment of neuroblastoma[J]. Expert Rev Anticancer Ther, 2017,17(4): 369-386.
[35]
Esposito M R, Aveic S, Seydel A, et al. Neuroblastoma treatment in the post-genomic era[J]. J Biomed Sci, 2017, 24(1): 14.
Cai J, Pan C, Lu Q, et al. Childhood renal tumor: a report from a Chinese Children’s Cancer Group[J]. Biomed Res Inter, 2016, 2014:894341.
[38]
Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma[J]. Expert Rev Anticancer Ther, 2017, 17(10): 889-904.
[40]
Siebert N, Zumpe M, Juttner M, et al. PD-1blockade augments anti-neuroblastoma immune response induced byanti-GD2 antibody ch14.18/CHO[J]. Oncoimmunology, 2017, 6 (10): e1343775.
[41]
Ladenstein S, Weixler B, Baykan M, et al. Ch14. 18antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study[J]. mAbs, 2013, 5 (5):801-809.
[42]
Yu A L, Gilman A L, Ozkaynak M F, et al. Children’s Oncology, Anti-GD2 antibody with GM-CSF interleukin-2, and isotretinoin for neuroblastoma[J]. N Engl J Med, 2010, 363(14): 1324-1334.
2018, Vol. 29 
